Financial News

Nicox to present at the 2017 BIO International Convention

Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced that Emmet Purtill, Director Business Development, will present at the 2017 BIO International Convention on Thursday June 22 , 2017 at 11:15 a.m. Pacific Time. The conference is being held at the Convention Center in San Diego.
The presentation will be available on Nicox website (www.nicox.com) in “Presentations &

Read more

Nicox announces the issuing and admission to trading on the Euronext regulated market in Paris of 597,897 new shares awarded to former Aciex shareholders following the US FDA’s approval of the new drug application in the US for ZERVIATE (cetirizine ophthalmic solution) 0.24%.

Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, has announced a capital increase of a nominal amount of €597,897 by means of the issuing and admission to trading on the Euronext regulated market in Paris of 597,897 new shares following the approval by the US FDA (Food and Drug Administration) of the new drug application in the US for ZERVIATE (cetirizine ophthalmic solution) 0.24% (see the Company’s press release of 31 May 2017),

Read more

Nicox receives FDA approval of ZERVIATE (cetirizine ophthalmic solution) 0.24%

  • First approved US NDA for Nicox
  • First topical ocular formulation of the antihistamine cetirizine
  • U.S. patent protection until at least 2030
  • Partnering discussions underway for U.S. commercialization rights

Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced that the U.S.

Read more
More news